ATE317844T1 - Adenosine a2a receptor antagonisten - Google Patents

Adenosine a2a receptor antagonisten

Info

Publication number: ATE317844T1
Authority: AT; Austria
Prior art keywords: adenosine; receptor antagonists; antagonists; receptor
Prior art date: 2001-11-30

Application number

AT02784641T

Other languages

English (en)

Inventor

Julius J Matasi

John P Caldwell

Deen Tulshian

Lisa S Silverman

Bernard R Neustadt

Original Assignee

Schering Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-11-30

Filing date

2002-11-26

Publication date

2006-03-15

2002-11-26 Application filed by Schering Corp filed Critical Schering Corp

2006-03-15 Application granted granted Critical

2006-03-15 Publication of ATE317844T1 publication Critical patent/ATE317844T1/de

Links

229940123702 Adenosine A2a receptor antagonist Drugs 0.000 title 1
239000002467 adenosine A2a receptor antagonist Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Biomedical Technology (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicinal Chemistry (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

AT02784641T 2001-11-30 2002-11-26 Adenosine a2a receptor antagonisten ATE317844T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US33429301P	2001-11-30	2001-11-30

Publications (1)

Publication Number	Publication Date
ATE317844T1 true ATE317844T1 (de)	2006-03-15

Family

ID=23306533

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02784641T ATE317844T1 (de)	2001-11-30	2002-11-26	Adenosine a2a receptor antagonisten

Country Status (18)

Country	Link
US (1)	US7041666B2 (de)
EP (1)	EP1453835B1 (de)
JP (2)	JP4284181B2 (de)
KR (1)	KR20050044607A (de)
CN (1)	CN1596258A (de)
AR (1)	AR038366A1 (de)
AT (1)	ATE317844T1 (de)
AU (1)	AU2002346572A1 (de)
CA (1)	CA2468681C (de)
DE (1)	DE60209251T2 (de)
ES (1)	ES2258164T3 (de)
HU (1)	HUP0402270A3 (de)
IL (1)	IL161572A0 (de)
MX (1)	MXPA04005156A (de)
PE (1)	PE20030739A1 (de)
TW (1)	TW200300686A (de)
WO (1)	WO2003048164A2 (de)
ZA (1)	ZA200404160B (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2004029056A1 (ja) *	2002-09-24	2004-04-08	Kyowa Hakko Kogyo Co., Ltd.	[１，２，４]トリアゾロ[１，５−ｃ]ピリミジン誘導体
TWI331036B (en)	2002-12-19	2010-10-01	Schering Corp	Adenosine a2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
US20060106040A1 (en)	2002-12-19	2006-05-18	Michael Grzelak	Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
WO2004092172A2 (en) *	2003-04-09	2004-10-28	Biogen Idec Ma Inc.	Triazolo[1,5-c]pyrimidines and pyrazolo[1,5-c]pyrimidines useful as a2a adenosin e receptor antagonists
WO2005039506A2 (en) *	2003-10-24	2005-05-06	Exelixis, Inc.	P70s6 kinase modulators and method of use
AR050926A1 (es)	2004-09-03	2006-12-06	Astrazeneca Ab	Derivados de benzamida como inhibidores de la histonadesacetilasa(hdac)
WO2006129626A1 (ja) *	2005-05-30	2006-12-07	Kyowa Hakko Kogyo Co., Ltd.	[1,2,4]トリアゾロ[1,5-c]ピリミジン誘導体の製造法
ES2273599B1 (es)	2005-10-14	2008-06-01	Universidad De Barcelona	Compuestos para el tratamiento de la fibrilacion auricular.
CA2687942A1 (en) *	2007-05-24	2008-12-04	Mitsubishi Tanabe Pharma Corporation	Therapeutic agent for cerebral infarction
CA2690748A1 (en) *	2007-06-25	2008-12-31	Neurogen Corporation	Piperazinyl oxoalkyl tetrahydro-beta-carbolines and related analogues
US20100093764A1 (en) *	2008-10-13	2010-04-15	Devraj Chakravarty	AMINES AND SULFOXIDES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
US20100093756A1 (en) *	2008-10-13	2010-04-15	Berbay J Kent	HETEROARYL SUBSTITUTED THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
BRPI0921570A2 (pt)	2008-11-25	2019-09-24	Nissan Motor	membro condutor de eletricidade e célula de combustível de eletrólito de polímero utilizando o mesmo
WO2010126811A1 (en) *	2009-04-27	2010-11-04	Boehringer Ingelheim International Gmbh	Cxcr3 receptor antagonists
WO2011084985A1 (en)	2010-01-07	2011-07-14	Boehringer Ingelheim International Gmbh	Cxcr3 receptor antagonists
AU2011306358B2 (en) *	2010-09-24	2014-08-14	Impetis Biosciences Ltd.	Fused tricyclic compounds as adenosine receptor antagonist
WO2012127472A1 (en) *	2011-03-22	2012-09-27	Mapi Pharma Ltd.	Process and intermediates for the preparation of preladenant and related compounds
PL3611174T3 (pl) *	2017-04-07	2022-08-08	Medshine Discovery Inc.	Pochodne [1,2,4]triazolo[1,5-c]pirymidyny jako inhibitor receptora a2a
TWI877770B (zh) *	2018-02-27	2025-03-21	美商英塞特公司	作為a2a / a2b抑制劑之咪唑并嘧啶及三唑并嘧啶
PL3766884T3 (pl) *	2018-04-28	2022-07-18	Medshine Discovery Inc.	Postać krystaliczna i rodzaj soli związku triazolopirymidynowego oraz sposób jej wytwarzania
EP3810610A1 (de) *	2018-05-18	2021-04-28	Incyte Corporation	Kondensierte pyrimidinderivate als a2a/a2b-inhibitoren
WO2020010197A1 (en)	2018-07-05	2020-01-09	Incyte Corporation	Fused pyrazine derivatives as a2a / a2b inhibitors
AR116315A1 (es) *	2018-09-12	2021-04-21	Dizal Jiangsu Pharmaceutical Co Ltd	Compuestos de triazolo-pirimidina y usos de los mismos
US12414952B2 (en)	2018-11-20	2025-09-16	Merck Sharp & Dohme Llc	Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
AU2019383948A1 (en)	2018-11-20	2021-05-20	Merck Sharp & Dohme Llc	Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
WO2020112700A1 (en)	2018-11-30	2020-06-04	Merck Sharp & Dohme Corp.	9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use
AU2019388872A1 (en)	2018-11-30	2021-05-27	Merck Sharp & Dohme Llc	7-, 8-, and 10-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use
CA3124088A1 (en)	2018-12-20	2020-06-25	Incyte Corporation	Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2
WO2020128036A1 (en) *	2018-12-21	2020-06-25	Ryvu Therapeutics S.A.	Modulators of the adenosine a2a receptor
TWI829857B (zh)	2019-01-29	2024-01-21	美商英塞特公司	作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU622330B2 (en)	1989-06-23	1992-04-02	Takeda Chemical Industries Ltd.	Condensed heterocyclic compounds having a nitrogen atom in the bridgehead for use as fungicides
IT1264901B1 (it)	1993-06-29	1996-10-17	Schering Plough S P A	Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina
WO1995003806A1 (en)	1993-07-27	1995-02-09	Kyowa Hakko Kogyo Co., Ltd.	Remedy for parkinson's disease
IT1277392B1 (it)	1995-07-28	1997-11-10	Schering Plough S P A	Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina
DE69820866T2 (de) *	1997-03-24	2004-12-30	Kyowa Hakko Kogyo Co., Ltd.	[1,2,4]TRIAZOLO[1,5-c]PYRIMIDIN-DERIVATE
IT1291372B1 (it)	1997-05-21	1999-01-07	Schering Plough S P A	Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
WO2000017201A1 (en) *	1998-09-22	2000-03-30	Kyowa Hakko Kogyo Co., Ltd.	[1,2,4]TRIAZOLO[1,5-c]PYRIMIDINE DERIVATIVES
DE60110219T2 (de)	2000-05-26	2006-03-09	Schering Corp.	Adenosin a2a rezeptor antagonisten
JPWO2002079204A1 (ja) *	2001-03-28	2004-07-22	協和醗酵工業株式会社	８−チアゾリル［１，２，４］トリアゾロ［１，５−ｃ］ピリミジン誘導体
IL161573A0 (en)	2001-11-30	2004-09-27	Schering Corp	[1,2,4]-TRIAZOLE BICYCLIC ADENOSINE A2a RECEPTOR ANTAGONISTS

2002
- 2002-11-25 AR ARP020104528A patent/AR038366A1/es unknown
- 2002-11-25 TW TW091134178A patent/TW200300686A/zh unknown
- 2002-11-25 PE PE2002001128A patent/PE20030739A1/es not_active Application Discontinuation
- 2002-11-26 AU AU2002346572A patent/AU2002346572A1/en not_active Abandoned
- 2002-11-26 CA CA2468681A patent/CA2468681C/en not_active Expired - Fee Related
- 2002-11-26 DE DE60209251T patent/DE60209251T2/de not_active Expired - Lifetime
- 2002-11-26 MX MXPA04005156A patent/MXPA04005156A/es active IP Right Grant
- 2002-11-26 AT AT02784641T patent/ATE317844T1/de not_active IP Right Cessation
- 2002-11-26 HU HU0402270A patent/HUP0402270A3/hu unknown
- 2002-11-26 ES ES02784641T patent/ES2258164T3/es not_active Expired - Lifetime
- 2002-11-26 JP JP2003549354A patent/JP4284181B2/ja not_active Expired - Fee Related
- 2002-11-26 IL IL16157202A patent/IL161572A0/xx unknown
- 2002-11-26 EP EP02784641A patent/EP1453835B1/de not_active Expired - Lifetime
- 2002-11-26 KR KR1020047008031A patent/KR20050044607A/ko not_active Withdrawn
- 2002-11-26 WO PCT/US2002/038134 patent/WO2003048164A2/en not_active Ceased
- 2002-11-26 US US10/304,504 patent/US7041666B2/en not_active Expired - Lifetime
- 2002-11-26 CN CNA028239229A patent/CN1596258A/zh active Pending
2004
- 2004-05-27 ZA ZA200404160A patent/ZA200404160B/en unknown
2008
- 2008-06-04 JP JP2008147394A patent/JP2008303217A/ja active Pending

Also Published As

Publication number	Publication date
DE60209251T2 (de)	2006-11-09
PE20030739A1 (es)	2003-08-28
AR038366A1 (es)	2005-01-12
KR20050044607A (ko)	2005-05-12
HUP0402270A2 (hu)	2005-02-28
TW200300686A (en)	2003-06-16
ES2258164T3 (es)	2006-08-16
ZA200404160B (en)	2005-04-08
HUP0402270A3 (en)	2008-09-29
MXPA04005156A (es)	2004-08-11
EP1453835A2 (de)	2004-09-08
CN1596258A (zh)	2005-03-16
IL161572A0 (en)	2004-09-27
US7041666B2 (en)	2006-05-09
AU2002346572A1 (en)	2003-06-17
CA2468681C (en)	2011-01-25
CA2468681A1 (en)	2003-06-12
HK1064100A1 (en)	2005-01-21
JP4284181B2 (ja)	2009-06-24
EP1453835B1 (de)	2006-02-15
US20030212080A1 (en)	2003-11-13
JP2008303217A (ja)	2008-12-18
JP2005511698A (ja)	2005-04-28
WO2003048164A2 (en)	2003-06-12
DE60209251D1 (de)	2006-04-20
WO2003048164A3 (en)	2003-10-16

Legal Events

Date	Code	Title	Description
2006-08-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE60209251D1 (de)	2006-04-20	Adenosine a2a receptor antagonisten
DE60110219D1 (de)	2005-05-25	Adenosin a2a rezeptor antagonisten
DE60234951D1 (de)	2010-02-11	Adenosin a2a rezeptor antagonisten
HUP0401925A3 (en)	2007-05-29	A2b adenosine receptor antagonists
PT1192169E (pt)	2003-09-30	C-pirazoles agonistas do receptor a2a
DE60219196D1 (de)	2007-05-10	BICYCLISCHE Ä1,2,4ö-TRIAZOL ADENOSIN A2a REZEPTOR ANTAGONISTEN
NO20032277D0 (no)	2003-05-20	Aminotiazoler og deres anvendelse som adenosinreseptorantagonister
IS5706A (is)	2000-11-07	Adenosín A3 viðtakastillar
ATE256141T1 (de)	2003-12-15	N-pyrazol a2a rezeptor agonisten
DK1446379T3 (da)	2009-07-27	Arylanilin-beta2-adrenergiske receptoragonister
HUP0401437A3 (en)	2007-05-29	Adenosine a3 receptor agonists
ATE432282T1 (de)	2009-06-15	2-alkinyl- und 2-alkenyl-pyrazolo-ä4,3-eü -1,2,4- triazolo-ä1,5-cü -pyrimidinadenosin a2a rezeptorantagonisten
IL175759A0 (en)	2006-09-05	A2b adenosine receptor antagonists
NO20020979L (no)	2002-04-26	Selektive A2B-adenosinreseptorantagonister
ATE394402T1 (de)	2008-05-15	Kondensierte purinderivate als a1- adenosinrezeptorantagonisten
ATE338043T1 (de)	2006-09-15	5-methoxy-8-aryl- 1,2,4ötriazolo 1,5-aöpyridine derivative als adenosin-rezeptor antagonisten
NO20033223L (no)	2003-07-16	Histamin-reseptor antagonister
EP1636230A4 (de)	2010-06-16	A1-adenosinrezeptorantagonisten
DE60220713D1 (de)	2007-07-26	Ribofuranosyluronamid Derivate als Kristall; ein menschlicher Adenosin A2A Rezeptor Agonsit
DE60209885D1 (de)	2006-05-11	Crf receptor antagonisten
SI1444233T1 (sl)	2011-11-30	Antagonisti adenozinskega receptorja A2B
EP1295891A4 (de)	2004-05-26	Nukleosidderivate
SE0003996D0 (sv)	2000-11-01	Receptorantagonister